Evidence map›Paper›PMID 21200062›Full record

ArticleAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2011

Development and implementation of a pharmacist-managed clinical pharmacogenetics service.

Kristine R Crews, Shane J Cross, John N McCormick, Donald K Baker, Alejandro R Molinelli, Richard Mullins, Mary V Relling, James M Hoffman

2 registry-linked trialsAbstract read
In one paragraph

Article in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 76 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 3 pooled it
25.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00137111 phase3completednot on this map

Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

TypeinterventionalSponsorSt. Jude Children's Research HospitalRan2000 to 2014Enrolled501ConditionsLymphoblastic Leukemia, AcuteArmsPrednisone, Dexamethasone, Vincristine, Daunorubicin, Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, Methotrexate, Cyclophosphamide, Cytarabine, Etoposide, Mercaptopurine, Imatinib, chemotherapy, intrathecal chemotherapy
NCT04727827 nacompletednot on this mapstarted 2021, after this paper: background citation

A Prospective Interventional Trial of Pharmacogenomic-Guided Supportive Care in Hematopoietic Cell Transplantation

TypeinterventionalSponsorWake Forest University Health SciencesRan2021 to 2023Enrolled110ConditionsHematopoietic Cell Transplantation, OncologyArmsPharmacogenomic-guided supportive care
3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 3 syntheses or guidelines pooled it, 154 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Trial
  5. Review
  6. Implementation of a pharmacist-guided pharmacogenomics dosing service at a rural NCI-designated comprehensive cancer center.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Cardiovascular precision medicine - A pharmacogenomic perspective.Cambridge prisms. Precision medicine · 2023
    Review
  12. Clinician adherence to pharmacogenomics prescribing recommendations in clinical decision support alerts.Journal of the American Medical Informatics Association : JAMIA · 2022
    Article
  13. Article
  14. Approaches to assessing the provider experience with clinical pharmacogenomic information: a scoping review.Genetics in medicine : official journal of the American College of Medical Genetics · 2021
    Article
  15. Article
  16. Article
  17. Precision Pharmacotherapy: Integrating Pharmacogenomics into Clinical Pharmacy Practice.Journal of the American College of Clinical Pharmacy : JACCP · 2019
    Article
  18. Preliminary outcomes of preemptive warfarin pharmacogenetic testing at a large rural healthcare center.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2019
    Article
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kristine R CrewsPharmaceutical Department, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA.
Shane J Cross
John N McCormick
Donald K Baker
Alejandro R Molinelli
Richard Mullins
Mary V Relling
James M Hoffman
Children's Healthcare of Atlanta · USUniversity of Tennessee Health Science Center · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
Whole GenomeU01GM061393 · NIGMS · UNIVERSITY OF CHICAGO · PI COX, NANCY J, DOLAN, MARY EILEEN · 2000 to 2014
$39.0M
PAARK4Kids-Pharmacogenomics of Anticancer Agents Research in ChildrenU01GM092666 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2014
$8.9M
NCI NIH HHS CA 21765NIGMS NIH HHS GM-92666NIGMS NIH HHS U01 GM061393NIGMS NIH HHS U01 GM092666
6 · The paper itself

Abstract

purposeThe development and implementation of a pharmacist-managed clinical pharmacogenetics service are described. SUMMARY: A pharmacist-managed clinical pharmacogenetics service was designed and implemented at an academic specialty hospital to provide clinical pharmacogenetic testing for gene products important to the pharmacodynamics of medications used in the hospital's patients. A series of accredited educational seminars were conducted for our pharmacists to establish competencies in providing pharmacogenetic consults for the genes to be tested by the clinical pharmacogenetics service. The service was modeled after and integrated with an already-established clinical pharmacokinetics service. A steering committee was formed to evaluate the use of available tests, new evidence for implementation of additional tests, and other service quality metrics. All clinical pharmacogenetic test results are first reported to one of the pharmacists, who reviews the result and provides a written consultation. The consultation includes an interpretation of the result and recommendations for any indicated changes to therapy. In 2009, 136 clinical pharmacogenetic tests were performed. The service has been met with positive clinician feedback. The successful implementation of this service highlights the leadership role that pharmacists can take in moving pharmacogenetics from research to patient care.

conclusionThe development of and experience with a pharmacist-managed clinical pharmacogenetics service are described. The program's success has depended on collaboration between the clinical laboratory and pharmacists, and pharmacists' pharmacogenetic recommendations have been well accepted by prescribers.

Indexed as

PharmacistsProfessional RoleProgram DevelopmentGenetic TestingHumansPharmaceutical ServicesPharmacogenetics

Identifiers

PMID21200062
PMCPMC3228517
OpenAlexW2114476310

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.